Dr. George R. Simon, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 61
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
FL license ME83970 -
Hematology (Internal Medicine) Physician
FL license ME83970 · SC license 30373 -
Hematology & Oncology Physician
PA license 435665
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 61
- Services billed
- 145
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 121 | 57 |
| New patient office or other outpatient visit, 60-74 minutes | 58 | 58 |
| Established patient office or other outpatient visit, 30-39 minutes | 28 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Celebration, FL | 30 |
| Tagrisso (osimertinib mesylate) | 20 |
| Iressa (gefitinib) | 12 |
| Lorbrena (lorlatinib) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 16 payments worth $19,355 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $15,320 |
|---|---|
| Novocure Inc. | $2,834 |
| AbbVie Inc. | $981 |
| Coherus Oncology, Inc. | $109 |
| AstraZeneca Pharmaceuticals LP | $79.21 |
| Bayer HealthCare Pharmaceuticals Inc. | $31.46 |
| Compensation for services other than consulting (speaking, faculty) | $14,703 |
|---|---|
| Honoraria | $2,800 |
| Consulting Fee | $906 |
| Travel and Lodging | $617 |
| Food and Beverage | $328 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $7,344 |
| Novocure Inc. May 23, 2025 | Honoraria Optune Lua (NovoTTF-200T) · Oncology | $2,800 |
| Regeneron Healthcare Solutions, Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $2,295 |
| Regeneron Healthcare Solutions, Inc. Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $1,515 |
| Regeneron Healthcare Solutions, Inc. Jun 17, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $1,301 |
| Regeneron Healthcare Solutions, Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $1,301 |
| Regeneron Healthcare Solutions, Inc. Jul 25, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $949 |
| Regeneron Healthcare Solutions, Inc. Oct 2, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to ATLANTA, GA · in-kind | $617 |
| AbbVie Inc. Jun 24, 2025 | Consulting Fee | $544 |
| AbbVie Inc. Nov 4, 2025 | Consulting Fee | $363 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $1,311 in research payments for these studies, mostly to the institutions running them.
- Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
AbbVie Inc. · Active, not recruiting · NCT03539536
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.